A global cancer data integrator reveals principles of synthetic lethality, sex disparity and immunotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-994X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A global cancer data integrator reveals principles of synthetic lethality, sex disparity and immunotherapy ; volume:13 ; number:1 ; day:18 ; month:10 ; year:2021 ; pages:1-12 ; date:12.2021
Genome medicine ; 13, Heft 1 (18.10.2021), 1-12, 12.2021
- Urheber
-
Yogodzinski, Christopher
Arab, Abolfazl
Pritchard, Justin R.
Goodarzi, Hani
Gilbert, Luke A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13073-021-00987-8
- URN
-
urn:nbn:de:101:1-2022011121070887898841
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yogodzinski, Christopher
- Arab, Abolfazl
- Pritchard, Justin R.
- Goodarzi, Hani
- Gilbert, Luke A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Modeling synthetic lethality
Epigenetic synthetic lethality approaches in cancer therapy
Advances in synthetic lethality modalities for glioblastoma multiforme
Telomere dysfunction and synthetic lethality in chronic lymphocytic leukemia
Exploiting genetic vulnerabilities for BAP1 loss by synthetic lethality
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
Synthetic lethality in lung cancer and translation to clinical therapies
Benchmarking machine learning methods for synthetic lethality prediction in cancer
Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors
Development of synthetic lethality in cancer: molecular and cellular classification
Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality
Harnessing synthetic lethality to predict the response to cancer treatment
Modeling synthetic lethality
Epigenetic synthetic lethality approaches in cancer therapy
Advances in synthetic lethality modalities for glioblastoma multiforme
Telomere dysfunction and synthetic lethality in chronic lymphocytic leukemia
Exploiting genetic vulnerabilities for BAP1 loss by synthetic lethality
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
Synthetic lethality in lung cancer and translation to clinical therapies
Benchmarking machine learning methods for synthetic lethality prediction in cancer
Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors
Development of synthetic lethality in cancer: molecular and cellular classification
Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality
Harnessing synthetic lethality to predict the response to cancer treatment
Modeling synthetic lethality
Epigenetic synthetic lethality approaches in cancer therapy
Advances in synthetic lethality modalities for glioblastoma multiforme
Telomere dysfunction and synthetic lethality in chronic lymphocytic leukemia
Exploiting genetic vulnerabilities for BAP1 loss by synthetic lethality
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
Synthetic lethality in lung cancer and translation to clinical therapies
Benchmarking machine learning methods for synthetic lethality prediction in cancer
Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors
Development of synthetic lethality in cancer: molecular and cellular classification
Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality